Life science
-
A new era for EU Merger control?
Key takeaways from the draft 2026 Merger Guidelines and practical advice.
-
DOJ signals assertive enforcement of life sciences sector at PCC
For compliance professionals attending the annual conference, the takeaway was hard to miss: 2026 will require a more rigorous compliance framework and transparency.
-
Fujifilm blazes a trail through pharma’s ethical quagmire
As advancements in research and drug development become more complex, bioethicists are helping companies find their footing along an increasingly ambiguous path.
-
EC consults on high-risk AI systems in life sciences and healthcare
Many life sciences and healthcare companies develop or deploy AI-based medical devices and digital health solutions that may fall within the high-risk category.
-
Celito Tech’s Ravi Monangi and Ethan Grammer on compliant growth in life science
We explored how small and mid-sized pharmaceutical and biotech companies can avoid costly early compliance mistakes and minimize risk as they scale.